B. Riley Equities Analysts Cut Earnings Estimates for NKTR
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Analysts at B. Riley decreased their Q1 2025 earnings estimates for Nektar Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($0.21) per share for the quarter, down from their previous estimate […]
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Analysts at B. Riley decreased their Q1 2025 earnings estimates for Nektar Therapeutics in a research note issued to investors on Monday, May 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($0.21) per share for the quarter, down from their previous estimate […]
